Fiche publication
Date publication
octobre 2024
Journal
Neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, Labauge P, De Sèze J, Vukusic S, Laplaud DA, Papeix C, Moreau T, Thouvenot E, Defer G, Lebrun-Frénay C, Ciron J, Berger E, Stankoff B, Clavelou P, Maillart E, Heinzlef O, Zéphir H, Ruet A, Casez O, Moulin S, Al-Khedr A, Bourre B, Pelletier J, Magy L, Neau JP, Camdessanché JP, Doghri I, Wahab A, Tchikviladzé M, Labeyrie C, Hankiewicz K, Le Page E, Michel L,
Lien Pubmed
Résumé
Although rituximab failed to demonstrate a significant effect on disability progression in primary progressive multiple sclerosis (PPMS), ocrelizumab succeeded. Our main objective was to analyze confirmed disability progression (CDP) in a cohort of patients with PPMS treated with anti-CD20 therapies compared with a weighted untreated control cohort.
Mots clés
Humans, Female, Male, Middle Aged, Multiple Sclerosis, Chronic Progressive, drug therapy, Retrospective Studies, Rituximab, therapeutic use, Immunologic Factors, therapeutic use, Antigens, CD20, immunology, Disease Progression, Antibodies, Monoclonal, Humanized, therapeutic use, Registries, Magnetic Resonance Imaging, France, epidemiology, Treatment Outcome
Référence
Neurology. 2024 10 22;103(8):e209886
